Descrizione del progetto
Fornire supporto d’organo ai pazienti Covid-19
Quasi il 60 % dei pazienti in unità di terapia intensiva muore per insufficienza multiorgano. È stato dimostrato che il dispositivo ADVOS migliora la sopravvivenza dei pazienti critici fino al 30 % attraverso la purificazione del sangue e la rimozione dell’anidride carbonica, il che riduce la necessità di supporto ventilatorio. Il progetto ADVOS-COVID-19, finanziato dall’UE, si propone di rendere disponibile il sistema ADVOS ai pazienti Covid-19 ricoverati in terapia intensiva, accelerando la produzione e l’installazione del dispositivo in Germania e in altri paesi dell’UE. L’idea è di supportare più pazienti in terapia intensiva con ADVOS invece che con i dispositivi di emodialisi standard e di offrire un supporto avanzato per fegato, polmoni e reni.
Obiettivo
ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care. The first COVID-19 patient with MOF is being treated with ADVOS in Germany at present with promising results. ADVITOS is a SME instrument Phase 2 beneficiary: ADVOS 880349 for device usability improvement, IoT integration, and market expansion (2.3m€ grant). Following the urgent EU call for corona solutions, we apply now for the blended finance option to speed up device production and installation in Germany and other EU countries. The applied funding and equity is necessary in therapy application, service and sales resources as well as accelerated clinical evidence for medical indication guidance. Integrating fluid-based blood oxygenation for comprehensive lung support and AI/digital capabilities will achieve additional therapy and outcome improvement. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the 1st and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current Corona crisis.
The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile). This relates especially to the removal of CO2 (by ADVOS) which relieves the lung and reduces the need/invasiveness of ventilation.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-EIC-SMEInst-2018-2020-3
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
80992 Munich
Germania
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.